- Home
- SVRE vs PRPO Comparison
SVRE vs PRPO Comparison
Compare SVRE & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRE
- PRPO
- Stock Information
- Founded
- SVRE 2014
- PRPO N/A
- Country
- SVRE Israel
- PRPO United States
- Employees
- SVRE N/A
- PRPO N/A
- Industry
- SVRE
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- SVRE
- PRPO Industrials
- Exchange
- SVRE Nasdaq
- PRPO Nasdaq
- Market Cap
- SVRE 2.6M
- PRPO 10.3M
- IPO Year
- SVRE 2022
- PRPO N/A
- Fundamental
- Price
- SVRE $0.12
- PRPO $6.69
- Analyst Decision
- SVRE
- PRPO
- Analyst Count
- SVRE 0
- PRPO 0
- Target Price
- SVRE N/A
- PRPO N/A
- AVG Volume (30 Days)
- SVRE 4.9M
- PRPO 7.9K
- Earning Date
- SVRE 08-27-2024
- PRPO 11-11-2024
- Dividend Yield
- SVRE N/A
- PRPO N/A
- EPS Growth
- SVRE N/A
- PRPO N/A
- EPS
- SVRE N/A
- PRPO N/A
- Revenue
- SVRE $458,952.00
- PRPO $16,719,999.00
- Revenue This Year
- SVRE N/A
- PRPO $75.18
- Revenue Next Year
- SVRE $422.52
- PRPO N/A
- P/E Ratio
- SVRE N/A
- PRPO N/A
- Revenue Growth
- SVRE N/A
- PRPO 52.61
- 52 Week Low
- SVRE $0.12
- PRPO $4.31
- 52 Week High
- SVRE $1.50
- PRPO $8.99
- Technical
- Relative Strength Index (RSI)
- SVRE 30.03
- PRPO 52.72
- Support Level
- SVRE $0.13
- PRPO $6.42
- Resistance Level
- SVRE $0.14
- PRPO $6.99
- Average True Range (ATR)
- SVRE 0.01
- PRPO 0.34
- MACD
- SVRE 0.00
- PRPO -0.04
- Stochastic Oscillator
- SVRE 20.63
- PRPO 68.59
About SVRE SaverOne 2014 Ltd.
Saverone 2014 Ltd provides driver protection solutions. The company develops and deploys ADAS technologies for transportation safety and driver assistance. The company's product restricts the driver from surfing, communicating, and receiving alerts while driving. The Company has developed a system that provides a solution to the problem of distracted driving caused by cell phone use, which endangers the driver, passengers, other drivers on the road, and pedestrians.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.